# V35 Queue: Autonomous One-Hour Self-Chaining Exploration Block

Block start UTC: 2026-06-07T16:37:36Z
Target block end UTC: 2026-06-07T17:37:36Z

## Iteration Log

### Iteration 1

- Start UTC: 2026-06-07T16:37:36Z
- Status: completed
- Item selected: EBV/IFN APC imprint grounding.
- Note: OpenGWAS verified; `SAP_AI_CORE_API_KEY` present.
- Result: needs data / not currently testable as EBV-specific. MS-SLE rg and
  V26 IFN/APC structure support prioritization, but current held data lack
  EBV-serostatus/viral-load stratification and EBV-latency genes (`EBNA1`,
  `LMP1`, `LMP2A`) in usable expression panels.

### Iteration 2

- Start UTC: 2026-06-07T16:40:04Z
- Status: completed
- Item selected: Postpartum APC-arm imbalance, MS-specificity.
- Note: Scout reachable MS postpartum/pregnancy immune data; if unavailable,
  stress-test cross-disease heterogeneity and specify exact cohort need.
- Result: partially grounded / MS postpartum data still missing. Local
  `GSE17410/GSE17449` has MS PBMC before/during pregnancy and relapse-vs-free
  description, but no postpartum timepoints and no local normalized expression
  matrix for immediate module scoring. Cross-disease heterogeneity shows
  CD64-shift dominated decoupling in healthy/SLE/SNRA and HLA-II-rebound
  dominated decoupling in SPRA.

### Iteration 3

- Start UTC: 2026-06-07T16:41:26Z
- Status: completed
- Item selected: Complement/lipid progressive axis.
- Note: Test against reachable progressive/chronic-active lesion data or report
  exact data gap.
- Result: partially grounded. Local GSE180759 supports a lipid-repair immune
  component at chronic-active lesion edge, but complement/phagocytosis and
  IFN/HLA/APC are not uniquely elevated versus control white matter in the quick
  module summary. Needs donor-aware pathology comparison.

### Iteration 4

- Start UTC: 2026-06-07T16:44:32Z
- Status: completed
- Item selected: T/B compartment remodeling gate.
- Note: Test on existing single-cell/compartment data and null-test where
  feasible.
- Result: supported but small-n. Exact V23 tofacitinib compartment scores show
  T/B-like compartments with mean locked-rule AUC `0.975` versus non-T/B mean
  `0.817`; exact patient-label permutation of the T/B-minus-non-T/B gap gives
  p `0.0635` over `126` label assignments.

### Iteration 5

- Start UTC: 2026-06-07T16:46:10Z
- Status: completed
- Item selected: Lysosomal APC-processing bottleneck.
- Note: Test cathepsin/V-ATPase/lysosomal-flux modules in APC/immune data and
  report whether existing perturbation data is sufficient.
- Result: reframed. V26 Mixscale perturbation modules support a coupled
  lysosomal APC arm (`gilt_lysosomal_apc` vs `ifn_apc` Spearman `0.902`,
  permutation p `0.00010`; vs `hla_ii_apc` Spearman `0.547`, p `0.0066`), but
  do not prove a functional antigen-processing bottleneck.

### Iteration 6

- Start UTC: 2026-06-07T16:48:03Z
- Status: completed
- Item selected: Metabolic/sterol setpoint.
- Note: Ground against existing metabolic module data and relate to V32
  immune-tone confounding.
- Result: supported as context axis, not intervention-grade. V32
  metabolic/inflammatory/STAT1 joint adjustment attenuates the monitoring
  signal (AUC `0.811` to `0.656`); ST003328 shows higher cholesterol in
  progressive MS-derived iNSC models and simvastatin lowering; GSE180759 shows
  modest cholesterol-synthesis transcript elevation at chronic-active lesion
  edge immune cells.

### Iteration 7

- Start UTC: 2026-06-07T16:52:14Z
- Status: completed
- Item selected: Two-lineage cross-examination of grounded hypotheses.
- Note: Ask Claude and Gemini for fatal weakness/strongest test of the grounded
  V35 shortlist; use as prioritization only, not evidence.
- Result: completed. Claude and Gemini converged on T/B gate replication as the
  highest-priority validation need; identified postpartum MS as data-acquisition
  blocked; and selected donor-aware complement/lipid lesion-edge testing as the
  highest-priority executable hardening step.

### Iteration 8

- Start UTC: 2026-06-07T16:54:30Z
- Status: completed
- Item selected: Donor-aware complement/lipid progressive-axis hardening.
- Note: Execute the convergent two-lineage next test on local GSE180759 using
  donor/case-aware summaries where metadata supports it.
- Result: downgraded. Donor-level immune-cell aggregation removes the clean
  chronic-active edge claim: complement is not elevated and lipid repair is only
  weak/directional, not statistically hardened.

### Iteration 9

- Start UTC: 2026-06-07T16:57:06Z
- Status: completed
- Item selected: T/B gate fragility check.
- Note: Stress-test the n=9 tofacitinib T/B signal for leave-one-patient and
  W48 timepoint leverage.
- Result: fragile but not collapsed. Excluding the lone W48 patient keeps the
  T/B-minus-non-T/B AUC gap at `0.156`; all leave-one-patient gaps remain
  positive (`0.115` to `0.211`).

### Iteration 10

- Start UTC: 2026-06-07T16:58:36Z
- Status: completed
- Item selected: GSE17410/GSE17449 postpartum-MS feasibility check.
- Note: Determine whether local pregnancy MS files can support HLA-II/CD64
  module scoring now or only metadata-level cohort specification.
- Result: pregnancy-phase scoring feasible, postpartum window absent. Local SOFT
  expression tables contain `21` HLA-II probes and `3` CD64 probes; month-9 MS
  pregnancy increases CD64 and lowers HLA-II-minus-CD64, including paired
  title-key delta `-1.168`, p `0.0432`, but no postpartum samples exist.

### Iteration 11

- Start UTC: 2026-06-07T17:05:12Z
- Status: completed
- Item selected: EBV-response module acquisition feasibility.
- Note: Find whether an EBV/LMP1/EBNA response module can be built from local or
  reachable public data now, without claiming EBV-specific biology until tested.
- Result: acquired host EBV-transformation module from GSE162516. Downloaded
  processed archive, checksum recorded, parsed `44,714` genes and built top
  host late-transformation up/down modules. Viral EBNA/LMP rows are absent from
  the human gene table; patient MS/SLE imprint remains untested.

### Iteration 12

- Start UTC: 2026-06-07T17:07:38Z
- Status: completed
- Item selected: EBV module IFN/APC separability.
- Note: Test whether the acquired host EBV-transformation module is distinct
  from generic IFN/APC within GSE162516 before using it on patient data.
- Result: source-module separable. Top-100 EBV-up/down genes have zero fixed
  IFN/APC overlap; EBV-up trajectory is negatively correlated with IFN/APC
  across GSE162516 (`r = -0.886`, p `0.0188`).

### Iteration 13

- Start UTC: 2026-06-07T17:09:21Z
- Status: completed
- Item selected: EBV module portability in local MS PBMC data.
- Note: Score acquired host EBV module in GSE17410/GSE17449 as a technical
  portability test only; no EBV-imprint claim without EBV metadata.
- Result: portable with coverage, not EBV-specific evidence. GPL571 has `117`
  top-100 EBV-up probes and `161` EBV-down probes; EBV-up does not rise in
  month-9 pregnancy, while EBV-down rises. No EBV metadata or SLE comparator.

### Iteration 14

- Start UTC: 2026-06-07T17:10:55Z
- End UTC: 2026-06-07T17:14:01Z
- Status: completed
- Item selected: Local SLE/B-cell/APC EBV-module scoring scout.
- Note: Search held local data for a SLE or B-cell/APC expression dataset where
  the acquired host EBV module can be scored with IFN/APC adjustment.
- Result: supported as a host EBV-module-like SLE blood state, not an EBV
  imprint claim. Local GSE108497 SLE/healthy pregnancy blood supports scoring
  the GSE162516 host EBV-transformation module (`145` EBV-up probes, `154`
  EBV-down probes). EBV-up is not correlated with IFN/APC (`rho = -0.062`,
  p `0.165`) and remains higher in SLE after linear IFN residualization
  (delta `9.102`, p `4.63e-17`). The dataset lacks EBV serostatus or viral-load
  metadata, so this cannot establish EBV causality.

### Iteration 15

- Start UTC: 2026-06-07T17:14:01Z
- End UTC: 2026-06-07T17:17:58Z
- Status: completed
- Item selected: Sorted SLE immune-subset EBV-module feasibility.
- Note: Test whether local sorted-cell SLE data (`GSE10325` or similar) can
  localize the host EBV-module-like signal to B-cell/APC compartments.
- Result: inconclusive compartment localization. GSE10325 sorted SLE/control
  CD4 T, CD19 B, and myeloid cells can score the module (`119` EBV-up probes,
  `161` EBV-down probes). Raw EBV-up is higher in SLE CD19 B cells (delta
  `64.814`, p `0.047`) and CD4 T cells (delta `18.384`, p `0.047`), but after
  within-subset IFN/APC residualization only CD19 B remains directionally higher
  and is not significant (delta `50.007`, p `0.126`). No EBV metadata exist.

### Iteration 16

- Start UTC: 2026-06-07T17:17:58Z
- End UTC: 2026-06-07T17:20:23Z
- Status: completed
- Item selected: EBV-module null-testing robustness.
- Note: Add permutation/FDR accounting for the GSE108497 blood and GSE10325
  sorted-cell EBV-module results before any shortlist upgrade.
- Result: broad SLE blood host-module signal survives, sorted-cell localization
  does not. GSE108497 EBV-up residualized for IFN/APC has SLE-HC delta `9.102`
  with unstratified and timepoint-stratified permutation p `9.999e-05`, FDR
  `0.00040`. GSE10325 CD19 B residual contrast remains inconclusive
  (permutation p `0.175`, family FDR `0.351`).

### Iteration 17

- Start UTC: 2026-06-07T17:20:23Z
- End UTC: 2026-06-07T17:21:58Z
- Status: completed
- Item selected: EBV-module random-gene-set specificity control.
- Note: Test whether the GSE108497 IFN-residualized SLE signal is stronger than
  random same-size gene/probe modules, not merely a large-module artifact.
- Result: EBV-specific interpretation downgraded. The observed IFN-residualized
  SLE-HC EBV-up delta is `9.102`, but among `2,000` random same-size gene sets
  its percentile is only `0.759` (upper-tail empirical p `0.241`, two-sided
  p `0.514`). This supports a broad SLE host-state signal, not EBV-module
  specificity.

### Iteration 18

- Start UTC: 2026-06-07T17:21:58Z
- End UTC: 2026-06-07T17:23:00Z
- Status: blocked
- Item selected: Postpartum APC-arm imbalance relapse-label test in MS pregnancy data.
- Note: Use local GSE17410/GSE17449 pregnancy-phase expression and relapse
  metadata, if parseable, to test whether HLA-II/CD64 differs by pregnancy
  relapse label despite absent postpartum samples.
- Result: blocked by missing per-sample relapse labels. The local metadata
  repeats the study-level statement that relapsing and relapse-free patients
  were compared, but the held SOFT-derived table and V35 module-score table do
  not expose a reliable relapse-status column. Title prefixes such as `DD`,
  `RP`, `SDC`, and `GRA9p` are insufficient for a non-fabricated relapse label.

### Iteration 19

- Start UTC: 2026-06-07T17:23:00Z
- End UTC: 2026-06-07T17:24:42Z
- Status: blocked
- Item selected: T/B gate independent-cohort feasibility scout.
- Note: Search held treatment-response artifacts for another paired
  compartment-resolved cohort that can replicate the V35 T/B remodeling gate.
- Result: blocked for independent replication with currently held data. The only
  paired response-labeled exact compartment artifact is the already-used
  `GSE253006` tofacitinib cohort. Other held cohorts are scalar/module-level
  paired scores without T/B compartment resolution.

### Iteration 20

- Start UTC: 2026-06-07T17:24:42Z
- End UTC: 2026-06-07T17:24:42Z
- Status: completed
- Item selected: Lysosomal APC random-module specificity control.
- Note: Stress-test whether the V35 lysosomal APC coupling in V26 treatment
  response modules is stronger than arbitrary module-pair correlations.
- Timing note: iteration 20 was opened during rapid chaining before a separate
  start clock read; the timestamp was corrected to the next real `date -u`
  read rather than preserving an impossible future timestamp.
- Result: strongest within perturbation data but not cross-modality supported.
  `gilt_lysosomal_apc` vs `ifn_apc` is the top perturbation module-pair
  correlation among 6 pairs (`rho = 0.902`, permutation p `0.00050`, BH q
  `0.00150`), but V26 grades the pair `not_supported` because only one
  significant modality replicated it. This remains a coupled transcript-state
  observation, not a proven antigen-processing bottleneck.

### Iteration 21

- Start UTC: 2026-06-07T17:24:42Z
- Status: in_progress
- Item selected: Metabolic/sterol setpoint specificity and actionability review.
- Note: Stress-test whether the sterol/metabolic setpoint has enough specific
  disease and direction evidence to remain above context-only status.

## Backlog

| Priority | Item | Status | Current Result / Resume Note |
|---:|---|---|---|
| 1 | EBV/IFN APC imprint | done | Needs EBV-stratified MS/SLE B-cell/APC data; current held summaries cannot separate EBV imprint from generic IFN/APC. |
| 2 | Postpartum APC-arm imbalance, MS-specificity | done | Partially grounded; true MS postpartum relapse-window data missing. |
| 3 | Complement/lipid progressive axis | done | Partially grounded; lipid-repair immune component at chronic-active edge, complement not yet uniquely supported. |
| 4 | T/B compartment remodeling gate | done | Supported but small-n; T/B-like AUC advantage p=0.0635 by exact patient-label permutation in n=9 tofacitinib cohort. |
| 5 | Lysosomal APC-processing bottleneck | done | Reframed as coupled lysosomal APC arm; functional bottleneck remains unproven without lysosomal flux/HLA-peptidomics. |
| 6 | Metabolic/sterol setpoint | done | Supported as context axis; not intervention-grade without APC-resolved lipidomics/perturbation. |
| 7 | Two-lineage cross-examination of grounded hypotheses | done | Both lineages converged on T/B replication, postpartum data acquisition, and donor-aware complement/lipid hardening. |
| 8 | Donor-aware complement/lipid progressive-axis hardening | done | Downgraded: donor-level test supports lipid-repair context only; complement not supported. |
| 9 | T/B gate fragility check | done | Fragile but not collapsed; W48 exclusion and all leave-one-patient gaps remain positive. |
| 10 | GSE17410/GSE17449 postpartum-MS feasibility check | done | Pregnancy-phase HLA/CD64 scoring feasible; postpartum relapse-window data absent. |
| 11 | EBV-response module acquisition feasibility | done | Host EBV-transformation module acquired from GSE162516; not yet MS/SLE tested. |
| 12 | EBV module IFN/APC separability | done | Source module separable from IFN/APC by top-gene overlap and trajectory. |
| 13 | EBV module portability in local MS PBMC data | done | Portable to GPL571 PBMC data; no EBV-specific evidence without metadata. |
| 14 | Local SLE/B-cell/APC EBV-module scoring scout | done | GSE108497 supports IFN-residualized SLE host EBV-module-like blood signal; no EBV metadata, so not an EBV imprint claim. |
| 15 | Sorted SLE immune-subset EBV-module feasibility | done | GSE10325 supports only inconclusive CD19 B directional localization after IFN residualization; no EBV metadata. |
| 16 | EBV-module null-testing robustness | done | GSE108497 host EBV-module-like SLE signal survives timepoint-stratified label permutation; GSE10325 sorted-cell localization remains inconclusive. |
| 17 | EBV-module random-gene-set specificity control | done | EBV-specific interpretation failed random same-size module control; broad SLE host-state signal remains. |
| 18 | Postpartum APC-arm imbalance relapse-label test in MS pregnancy data | blocked | Local GSE17410/GSE17449 lacks reliable per-sample relapse labels; title prefixes are not sufficient. |
| 19 | T/B gate independent-cohort feasibility scout | blocked | No independent held compartment-resolved paired response cohort found beyond already-used GSE253006. |
| 20 | Lysosomal APC random-module specificity control | done | Strongest Mixscale module-pair correlation, but not cross-modality supported; remains not a bottleneck claim. |
| 21 | Metabolic/sterol setpoint specificity and actionability review | in_progress | Stress-test whether metabolic/sterol setpoint rises above context-only status. |

## Timing Rule

Each iteration must append its measured start and end UTC from `date -u`.
Continue chaining until cumulative measured active time is at least 60 minutes,
unless all backlog items are done/blocked or external termination occurs.
